Ipragliflozin (BioDeep_00000730170)
代谢物信息卡片
Ipragliflozin
化学式: C21H21FO5S (404.10936680000003)
中文名称: 伊格列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F
InChI: InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134724
- KEGGdrug: D10196
- PubChem: 10453870
- DrugBank: DB11698
- ChEMBL: CHEMBL2018096
- CAS: 761423-87-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Minju Park, Seo-Yeong Mun, Wenwen Zhuang, Junsu Jeong, Hye Ryung Kim, Hongzoo Park, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun, Hongliang Li, Won Sun Park. The antidiabetic drug ipragliflozin induces vasorelaxation of rabbit femoral artery by activating a Kv channel, the SERCA pump, and the PKA signaling pathway.
European journal of pharmacology.
2024 Jun; 972(?):176589. doi:
10.1016/j.ejphar.2024.176589. [PMID: 38631503] - Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study.
Cardiovascular diabetology.
2024 02; 23(1):56. doi:
10.1186/s12933-024-02149-7. [PMID: 38331780] - Linli Zhang, Fan Zhang, Yan Bai, Liuyan Huang, Yifei Zhong, Xianwen Zhang. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.
BMJ open diabetes research & care.
2024 Jan; 12(1):. doi:
10.1136/bmjdrc-2023-003836. [PMID: 38238025] - Hiroshi Akasaka, Ken Sugimoto, Ayumi Shintani, Satsuki Taniuchi, Koichi Yamamoto, Katsuomi Iwakura, Atsunori Okamura, Shin Takiuchi, Masahiro Fukuda, Kei Kamide, Yasushi Fujio, Satoshi Nakatani, Toshio Ogihara, Hiromi Rakugi. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Geriatrics & gerontology international.
2022 Apr; 22(4):298-304. doi:
10.1111/ggi.14363. [PMID: 35212104] - Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, Amirhossein Sahebkar. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Journal of diabetes research.
2022; 2022(?):7520632. doi:
10.1155/2022/7520632. [PMID: 35224108] - Asahiro Morishita, Tomoko Tadokoro, Shintaro Fujihara, Hisakazu Iwama, Kyoko Oura, Koji Fujita, Joji Tani, Kei Takuma, Mai Nakahara, Tingting Shi, Reiji Haba, Keiichi Okano, Akira Nishiyama, Masafumi Ono, Takashi Himoto, Tsutomu Masaki. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
PloS one.
2022; 17(2):e0261310. doi:
10.1371/journal.pone.0261310. [PMID: 35192632] - Atsuo Tahara. SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
European journal of pharmacology.
2021 Nov; 910(?):174486. doi:
10.1016/j.ejphar.2021.174486. [PMID: 34487707] - Masao Koike, Hitoki Saito, Genta Kohno, Masahiro Takubo, Kentaro Watanabe, Hisamitsu Ishihara. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
International journal of molecular sciences.
2021 Oct; 22(21):. doi:
10.3390/ijms222111463. [PMID: 34768897] - Hideyuki Okuma, Kentaro Mori, Suguru Nakamura, Tetsuo Sekine, Yoshihiro Ogawa, Kyoichiro Tsuchiya. Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
International journal of molecular sciences.
2021 Jul; 22(14):. doi:
10.3390/ijms22147329. [PMID: 34298949] - Atsuo Tahara. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
European journal of pharmacology.
2021 Jun; 901(?):174076. doi:
10.1016/j.ejphar.2021.174076. [PMID: 33798599] - Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A O'Neill, Samuel S Engel, Keith D Kaufman. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Diabetes, obesity & metabolism.
2021 06; 23(6):1342-1350. doi:
10.1111/dom.14346. [PMID: 33565686] - Akira Kurozumi, Yosuke Okada, Yoshiya Tanaka. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Endocrine journal.
2021 Mar; 68(3):361-369. doi:
10.1507/endocrj.ej20-0577. [PMID: 33208570] - Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Satoshi Uno. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Expert opinion on pharmacotherapy.
2021 Feb; 22(3):373-387. doi:
10.1080/14656566.2020.1817388. [PMID: 33012212] - Ahmed Elgebaly, Nesrine Abdelazeim, Bassant Abdelazeim, Gehad El Ashal, Omar Mattar, Lubaba Namous, Noha Nasreldin. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
2021 Jan; 129(1):56-72. doi:
10.1055/a-0579-7860. [PMID: 29913526] - Wajd Alkabbani, John-Michael Gamble. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Drug design, development and therapy.
2021; 15(?):3057-3069. doi:
10.2147/dddt.s281602. [PMID: 34285473] - Daisuke Inoue, Hiroshi Nishi, Reiko Inoue, Masaomi Nangaku. Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
International heart journal.
2021; 62(3):592-600. doi:
10.1536/ihj.20-716. [PMID: 34054000] - Kazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, Yoshinobu Nakamaru, Takayuki Takahata, Ryuta Saito. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Biopharmaceutics & drug disposition.
2020 Nov; 41(8-9):352-366. doi:
10.1002/bdd.2253. [PMID: 33085977] - Junko Toyoshima, Masako Saito, Atsunori Kaibara, Hiroyuki Isaka, Taishi Sakatani. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Clinical therapeutics.
2020 09; 42(9):1787-1798.e3. doi:
10.1016/j.clinthera.2020.07.009. [PMID: 32839028] - Shusuke Fukuoka, Kaoru Dohi, Tetsushiro Takeuchi, Keishi Moriwaki, Masaki Ishiyama, Taku Omori, Naoki Fujimoto, Masaaki Ito. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Heart and vessels.
2020 Sep; 35(9):1218-1226. doi:
10.1007/s00380-020-01597-x. [PMID: 32270357] - Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Journal of diabetes investigation.
2020 Sep; 11(5):1248-1257. doi:
10.1111/jdi.13248. [PMID: 32149469] - Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Kazuhiro Sugimoto, Akira Kurozumi, Keiichi Torimoto, Hiroyuki Hirai, Koichi Node. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Cardiovascular diabetology.
2020 06; 19(1):85. doi:
10.1186/s12933-020-01065-w. [PMID: 32534578] - F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Journal of medicinal chemistry.
2020 05; 63(10):5031-5073. doi:
10.1021/acs.jmedchem.9b01701. [PMID: 31930920] - Miho Nakamura, Junya Nakade, Tadashi Toyama, Masaki Okajima, Takumi Taniguchi. Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report.
BMC pharmacology & toxicology.
2020 01; 21(1):5. doi:
10.1186/s40360-019-0381-z. [PMID: 31918741] - Momoko Habu, Yosuke Okada, Akira Kurozumi, Yoshiya Tanaka. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Journal of UOEH.
2020; 42(4):359-364. doi:
10.7888/juoeh.42.359. [PMID: 33268615] - Masashi Tanaka, Hajime Yamakage, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Akira Shimatsu, Noriko Satoh-Asahara. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Internal medicine (Tokyo, Japan).
2020; 59(5):601-609. doi:
10.2169/internalmedicine.3473-19. [PMID: 32115517] - Takahiro Masuda, Shigeaki Muto, Keiko Fukuda, Minami Watanabe, Ken Ohara, Hermann Koepsell, Volker Vallon, Daisuke Nagata. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Physiological reports.
2020 01; 8(2):e14360. doi:
10.14814/phy2.14360. [PMID: 31994353] - Kohshiro Hosokawa, Tomoaki Takata, Takaaki Sugihara, Tomomitsu Matono, Masahiko Koda, Tsutomu Kanda, Sosuke Taniguchi, Ayami Ida, Yukari Mae, Marie Yamamoto, Takuji Iyama, Satoko Fukuda, Hajime Isomoto. Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
International journal of molecular sciences.
2019 Dec; 21(1):. doi:
10.3390/ijms21010190. [PMID: 31888083] - Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
European journal of medicinal chemistry.
2019 Dec; 184(?):111773. doi:
10.1016/j.ejmech.2019.111773. [PMID: 31630053] - Hisamitsu Ishihara, Susumu Yamaguchi, Toshifumi Sugitani, Yoshinori Kosakai. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Clinical drug investigation.
2019 Dec; 39(12):1213-1221. doi:
10.1007/s40261-019-00851-z. [PMID: 31552641] - You Cheol Hwang, Jae Hyeon Kim, Byung Wan Lee, Woo Je Lee. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Diabetes & metabolism journal.
2019 12; 43(6):898-905. doi:
10.4093/dmj.2018.0257. [PMID: 31237132] - Hongmei Wang, Gaoqiong Yao, Xi Chen, Jing Ouyang, Jiadan Yang. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Diabetes research and clinical practice.
2019 Nov; 157(?):107867. doi:
10.1016/j.diabres.2019.107867. [PMID: 31568801] - Reyhaneh Moradi-Marjaneh, Maryam Paseban, Amirhossein Sahebkar. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Phytotherapy research : PTR.
2019 Oct; 33(10):2518-2530. doi:
10.1002/ptr.6421. [PMID: 31359514] - Hiroshi Miura, Kazuhiko Sakaguchi, Yuko Okada, Tomoko Yamada, Natsu Otowa-Suematsu, Anna So, Hisako Komada, Yushi Hirota, Takeshi Ohara, Yasuo Kuroki, Kenta Hara, Tomokazu Matsuda, Minoru Kishi, Akihiko Takeda, Kazuki Yokota, Yoshikazu Tamori, Wataru Ogawa. Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Journal of diabetes investigation.
2019 Sep; 10(5):1254-1261. doi:
10.1111/jdi.13015. [PMID: 30688412] - Toshiyuki Takasu, Shoji Takakura. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Life sciences.
2019 Aug; 230(?):19-27. doi:
10.1016/j.lfs.2019.05.051. [PMID: 31125563] - Masako Saito, Atsunori Kaibara, Takeshi Kadokura, Junko Toyoshima, Satoshi Yoshida, Kenichi Kazuta, Eiji Ueyama. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
British journal of clinical pharmacology.
2019 08; 85(8):1808-1819. doi:
10.1111/bcp.13972. [PMID: 31026084] - Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, Yoshiro Maezawa, Kenichi Sakamoto, Daigaku Uchida, Susumu Nakamura, Masaya Yamaga, Hidetaka Yokoh, Akina Kobayashi, Shunichiro Onishi, Kazuki Kobayashi, Jun Ogino, Naotake Hashimoto, Hirotake Tokuyama, Fumio Shimada, Emi Ohara, Takahiro Ishikawa, Mayumi Shoji, Shintaro Ide, Kana Ide, Yusuke Baba, Akiko Hattori, Takumi Kitamoto, Takuro Horikoshi, Ryota Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Minoru Takemoto, Laura Kristin Newby, Koutaro Yokote. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Diabetes, obesity & metabolism.
2019 08; 21(8):1990-1995. doi:
10.1111/dom.13750. [PMID: 30993861] - Akira Yoshii, Tomohisa Nagoshi, Yusuke Kashiwagi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Keiichi Ito, Takuya Yoshino, Toshikazu D Tanaka, Michihiro Yoshimura. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Cardiovascular diabetology.
2019 07; 18(1):85. doi:
10.1186/s12933-019-0889-y. [PMID: 31262297] - Akira Kurozumi, Yosuke Okada, Mototsugu Shimokawa, Yukiko Goshima, Takashi Otsuka, Manabu Narisawa, Keiichi Torimoto, Yoshiya Tanaka. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Diabetes technology & therapeutics.
2019 07; 21(7):385-392. doi:
10.1089/dia.2019.0099. [PMID: 31210529] - Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima, Taishi Sakatani. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Diabetes, obesity & metabolism.
2019 06; 21(6):1445-1454. doi:
10.1111/dom.13679. [PMID: 30821047] - Kenichi Ishizawa, Qin Wang, Jinping Li, Ning Xu, Yoshikazu Nemoto, Chikayuki Morimoto, Wataru Fujii, Yoshifuru Tamura, Yoshihide Fujigaki, Kazuhisa Tsukamoto, Toshiro Fujita, Shunya Uchida, Shigeru Shibata. Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice.
Journal of the American Society of Nephrology : JASN.
2019 05; 30(5):782-794. doi:
10.1681/asn.2018070703. [PMID: 30914436] - Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Satoshi Uno. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Advances in therapy.
2019 04; 36(4):923-949. doi:
10.1007/s12325-019-0895-1. [PMID: 30767112] - Shoji Takakura, Toshiyuki Takasu. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
Clinical and experimental pharmacology & physiology.
2019 03; 46(3):266-273. doi:
10.1111/1440-1681.13053. [PMID: 30485488] - Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen, John-Michael Gamble. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
BMJ open.
2019 02; 9(1):e022577. doi:
10.1136/bmjopen-2018-022577. [PMID: 30813108] - Shoji Takakura, Toshiyuki Takasu. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Biological & pharmaceutical bulletin.
2019; 42(10):1707-1712. doi:
10.1248/bpb.b19-00351. [PMID: 31582658] - Kaoru Sugimoto, Ichiro Abe, Midori Minezaki, Yuichi Takashi, Kentaro Ochi, Hideyuki Fujii, Hanako Ohishi, Yuka Yamao, Tadachika Kudo, Kenji Ohe, Makiko Abe, Yasushi Ohnishi, Tomohiro Shinagawa, Shigeaki Mukoubara, Kunihisa Kobayashi. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Drug discoveries & therapeutics.
2019; 13(6):322-327. doi:
10.5582/ddt.2019.01085. [PMID: 31956230] - Shinji Tanaka, Yuki Sugiura, Hisako Saito, Mai Sugahara, Yoshiki Higashijima, Junna Yamaguchi, Reiko Inagi, Makoto Suematsu, Masaomi Nangaku, Tetsuhiro Tanaka. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Kidney international.
2018 11; 94(5):912-925. doi:
10.1016/j.kint.2018.04.025. [PMID: 30021702] - Yuya Tsurutani, Kazuki Nakai, Kosuke Inoue, Kosuke Azuma, Sei Mukai, Seitaro Maruyama, Takashi Iizuka, Yoko Matsuzawa, Jun Saito, Masao Omura, Tetsuo Nishikawa. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Diabetes, obesity & metabolism.
2018 11; 20(11):2675-2679. doi:
10.1111/dom.13421. [PMID: 29893003] - Yasutaka Miyachi, Kyoichiro Tsuchiya, Kumiko Shiba, Kentaro Mori, Chikara Komiya, Naomi Ogasawara, Yoshihiro Ogawa. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition.
Scientific reports.
2018 10; 8(1):16113. doi:
10.1038/s41598-018-34305-x. [PMID: 30382157] - Kyung-Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan-Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong-Sun Kim, Kyong Soo Park, Kun-Ho Yoon, In-Kyu Lee, Bong-Soo Cha, Taishi Sakatani, Sumi Park, Moon-Kyu Lee. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Diabetes, obesity & metabolism.
2018 10; 20(10):2408-2415. doi:
10.1111/dom.13394. [PMID: 29862619] - Atsuo Tahara, Yoshinori Kondo, Toshiyuki Takasu, Hiroshi Tomiyama. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2018 Sep; 105(?):1033-1041. doi:
10.1016/j.biopha.2018.06.062. [PMID: 30021338] - Susumu Takagi, Jinpeng Li, Yuta Takagaki, Munehiro Kitada, Kyoko Nitta, Toshiyuki Takasu, Keizo Kanasaki, Daisuke Koya. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
Journal of diabetes investigation.
2018 Sep; 9(5):1025-1032. doi:
10.1111/jdi.12802. [PMID: 29352520] - Takahiro Masuda, Yuko Watanabe, Keiko Fukuda, Minami Watanabe, Akira Onishi, Ken Ohara, Toshimi Imai, Hermann Koepsell, Shigeaki Muto, Volker Vallon, Daisuke Nagata. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
American journal of physiology. Renal physiology.
2018 09; 315(3):F653-F664. doi:
10.1152/ajprenal.00143.2018. [PMID: 29790389] - Takashi Nomiyama, Dai Shimono, Tsuyoshi Horikawa, Yuki Fujimura, Tomohiro Ohsako, Yuichi Terawaki, Takashi Fukuda, Ryoko Motonaga, Makito Tanabe, Toshihiko Yanase. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Endocrine journal.
2018 Aug; 65(8):859-867. doi:
10.1507/endocrj.ej18-0022. [PMID: 29806620] - Paula Nogueira da Silva, Raissa Alves da Conceição, Rodolfo do Couto Maia, Maria Leticia de Castro Barbosa. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
MedChemComm.
2018 Aug; 9(8):1273-1281. doi:
10.1039/c8md00183a. [PMID: 30151080] - Atsunori Kashiwagi, Taishi Sakatani, Ichiro Nakamura, Noriko Akiyama, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Yoshinori Kosakai. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Endocrine journal.
2018 Jul; 65(7):693-705. doi:
10.1507/endocrj.ej17-0491. [PMID: 29848902] - Atsuo Tahara, Toshiyuki Takasu. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
European journal of pharmacology.
2018 Jul; 830(?):68-75. doi:
10.1016/j.ejphar.2018.04.024. [PMID: 29702076] - Tomohiko Kimura, Junpei Sanada, Masashi Shimoda, Hidenori Hirukawa, Yoshiro Fushimi, Momoyo Nishioka, Tomoe Kinoshita, Seizo Okauchi, Atsushi Obata, Kenji Kohara, Fuminori Tatsumi, Shinji Kamei, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Journal of diabetes investigation.
2018 Jul; 9(4):875-881. doi:
10.1111/jdi.12774. [PMID: 29110406] - Atsuo Tahara, Toshiyuki Takasu. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Naunyn-Schmiedeberg's archives of pharmacology.
2018 04; 391(4):395-406. doi:
10.1007/s00210-018-1469-5. [PMID: 29374293] - Michitsugu Kamezaki, Tetsuro Kusaba, Kazumi Komaki, Yohei Fushimura, Noriko Watanabe, Kisho Ikeda, Takashi Kitani, Noriyuki Yamashita, Masahiro Uehara, Yuhei Kirita, Yayoi Shiotsu, Ryosuke Sakai, Takuya Fukuda, Masahiro Yamazaki, Michiaki Fukui, Satoaki Matoba, Keiichi Tamagaki. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Scientific reports.
2018 03; 8(1):4029. doi:
10.1038/s41598-018-22229-5. [PMID: 29507299] - Takeshi Osonoi, Shinya Nakamoto, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Yusuke Osonoi. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Journal of diabetes investigation.
2018 Mar; 9(2):341-353. doi:
10.1111/jdi.12705. [PMID: 28644562] - Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Ichiro Nakamura, Satoshi Uno. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Expert opinion on pharmacotherapy.
2018 Mar; 19(4):327-336. doi:
10.1080/14656566.2018.1434145. [PMID: 29388470] - Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Satoshi Uno. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Expert opinion on pharmacotherapy.
2018 Feb; 19(3):189-201. doi:
10.1080/14656566.2017.1408792. [PMID: 29185822] - Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
European journal of pharmacology.
2018 Jan; 818(?):545-553. doi:
10.1016/j.ejphar.2017.11.020. [PMID: 29154936] - Toshiyuki Sakaeda, Shinji Kobuchi, Ryosuke Yoshioka, Mariko Haruna, Noriko Takahata, Yukako Ito, Aki Sugano, Kazuki Fukuzawa, Toshiki Hayase, Taro Hayakawa, Hideo Nakayama, Yutaka Takaoka, Masahiro Tohkin. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
International journal of medical sciences.
2018; 15(9):937-943. doi:
10.7150/ijms.22224. [PMID: 30008607] - Toshiyuki Takasu, Shoji Takakura. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Biological & pharmaceutical bulletin.
2018; 41(5):761-769. doi:
10.1248/bpb.b17-01007. [PMID: 29709913] - Shunya Uchida, Takanori Kumagai, Wen Xiu Chang, Yoshifuru Tamura, Shigeru Shibata. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Contributions to nephrology.
2018; 192(?):56-68. doi:
10.1159/000484279. [PMID: 29393121] - Soichi Takeishi, Hiroki Tsuboi, Shodo Takekoshi. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Endocrine journal.
2017 Oct; 64(10):995-1005. doi:
10.1507/endocrj.ej17-0206. [PMID: 28824042] - Akihiko Takeda, Aya Irahara, Atsuko Nakano, Emi Takata, Yuko Koketsu, Kunie Kimata, Eri Senda, Hajime Yamada, Kazuhito Ichikawa, Takahiro Fujimori, Yoshio Sumida. The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Internal medicine (Tokyo, Japan).
2017 Oct; 56(20):2739-2744. doi:
10.2169/internalmedicine.8754-16. [PMID: 28924123] - Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito, Morifumi Yanagisawa, Kouichi Inukai, Yuji Akiyama, Yoshihiro Morimoto, Mitsuhiko Noda, Akira Shimada. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Diabetes care.
2017 10; 40(10):1364-1372. doi:
10.2337/dc17-0518. [PMID: 28751548] - Akio Ohta, Hiroyuki Kato, Satoshi Ishii, Yosuke Sasaki, Yuta Nakamura, Tomoko Nakagawa, Yoshio Nagai, Yasushi Tanaka. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Expert opinion on pharmacotherapy.
2017 Oct; 18(14):1433-1438. doi:
10.1080/14656566.2017.1363888. [PMID: 28770629] - Hiroyuki Iuchi, Masaya Sakamoto, Daisuke Matsutani, Hirofumi Suzuki, Yosuke Kayama, Norihiko Takeda, Susumu Minamisawa, Kazunori Utsunomiya. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Scientific reports.
2017 09; 7(1):11906. doi:
10.1038/s41598-017-12106-y. [PMID: 28928461] - Daigo Toyoki, Shigeru Shibata, Emiko Kuribayashi-Okuma, Ning Xu, Kenichi Ishizawa, Makoto Hosoyamada, Shunya Uchida. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
American journal of physiology. Renal physiology.
2017 09; 313(3):F826-F834. doi:
10.1152/ajprenal.00012.2017. [PMID: 28679589] - Mohsen Mazidi, Peyman Rezaie, Hong-Kai Gao, Andre Pascal Kengne. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Journal of the American Heart Association.
2017 May; 6(6):. doi:
10.1161/jaha.116.004007. [PMID: 28546454] - Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, Kazuki Kobayashi, Minoru Takemoto, Takuro Horikoshi, Ryota Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Ichiro Tatsuno, Takashi Terano, Naotake Hashimoto, Nobuichi Kuribayashi, Daigaku Uchida, Koutaro Yokote. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
BMJ open.
2017 05; 7(5):e015766. doi:
10.1136/bmjopen-2016-015766. [PMID: 28490565] - Fumitaka Okajima, Tomoko Nagamine, Yuko Nakamura, Naomi Hattori, Hitoshi Sugihara, Naoya Emoto. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Journal of diabetes investigation.
2017 May; 8(3):341-345. doi:
10.1111/jdi.12588. [PMID: 27762088] - Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
BMC pharmacology & toxicology.
2017 04; 18(1):23. doi:
10.1186/s40360-017-0125-x. [PMID: 28391776] - Jean-Luc Faillie. Pharmacological aspects of the safety of gliflozins.
Pharmacological research.
2017 04; 118(?):71-81. doi:
10.1016/j.phrs.2016.07.001. [PMID: 27389050] - Takahiro Takase, Akinobu Nakamura, Hideaki Miyoshi, Chiho Yamamoto, Tatsuya Atsumi. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Endocrine journal.
2017 Mar; 64(3):363-367. doi:
10.1507/endocrj.ej16-0295. [PMID: 27980239] - Yoshio Nagai, Akio Ohta, Yukiyoshi Sada, Hiroyuki Kato, Yasushi Tanaka. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Expert opinion on pharmacotherapy.
2017 Jan; 18(1):13-17. doi:
10.1080/14656566.2016.1261110. [PMID: 27841020] - Masaaki Miyauchi, Masao Toyoda, Masafumi Fukagawa. Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Internal medicine (Tokyo, Japan).
2017; 56(13):1673-1678. doi:
10.2169/internalmedicine.56.7945. [PMID: 28674356] - Takahiro Tosaki, Hideki Kamiya, Tatsuhito Himeno, Yoshiro Kato, Masaki Kondo, Kaori Toyota, Tomoyo Nishida, Megumi Shiroma, Kaori Tsubonaka, Hitomi Asai, Miho Moribe, Yuki Nakaya, Jiro Nakamura. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
Internal medicine (Tokyo, Japan).
2017; 56(6):597-604. doi:
10.2169/internalmedicine.56.7196. [PMID: 28321056] - Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Akira Okitsu, Seitaro Asahina. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Diabetes, obesity & metabolism.
2016 12; 18(12):1207-1216. doi:
10.1111/dom.12745. [PMID: 27436788] - Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C Del Gobbo, Suodi Zhai, Yiqing Song. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Diabetologia.
2016 12; 59(12):2546-2551. doi:
10.1007/s00125-016-4101-6. [PMID: 27628105] - Norihisa Nishimura, Mitsuteru Kitade, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Kosuke Takeda, Yasushi Okura, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani, Kiyoshi Asada, Hitoshi Yoshiji. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Journal of gastroenterology.
2016 Dec; 51(12):1141-1149. doi:
10.1007/s00535-016-1200-6. [PMID: 27025708] - Eiji Kutoh, Teruma Murayama, Asuka Wada, Mitsuru Hirate. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Drugs in R&D.
2016 Dec; 16(4):369-376. doi:
10.1007/s40268-016-0149-5. [PMID: 27798769] - Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Ichiro Nakamura. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Expert opinion on pharmacotherapy.
2016 Oct; 17(15):1985-94. doi:
10.1080/14656566.2016.1217994. [PMID: 27463414] - Aya Osaki, Shuichi Okada, Tsugumichi Saito, Eijiro Yamada, Kumeo Ono, Yawara Niijima, Hiroto Hoshi, Masanobu Yamada. Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.
Journal of diabetes investigation.
2016 Sep; 7(5):751-4. doi:
10.1111/jdi.12473. [PMID: 27181936] - Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Journal of diabetes investigation.
2016 Jul; 7(4):544-54. doi:
10.1111/jdi.12471. [PMID: 27181576] - Chiho Yamamoto, Hideaki Miyoshi, Kota Ono, Hajime Sugawara, Reina Kameda, Mei Ichiyama, Kohei Yamamoto, Hiroshi Nomoto, Akinobu Nakamura, Tatsuya Atsumi. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Endocrine journal.
2016 Jun; 63(6):589-96. doi:
10.1507/endocrj.ej15-0749. [PMID: 27052123] - Chieh-Hsiang Lu, Kyung Wan Min, Lee-Ming Chuang, Satoshi Kokubo, Satoshi Yoshida, Bong-Soo Cha. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Journal of diabetes investigation.
2016 05; 7(3):366-73. doi:
10.1111/jdi.12422. [PMID: 27330723] - Takamasa Ohki, Akihiro Isogawa, Nobuo Toda, Kazumi Tagawa. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Clinical drug investigation.
2016 Apr; 36(4):313-9. doi:
10.1007/s40261-016-0383-1. [PMID: 26914659] - Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Journal of pharmacological sciences.
2016 Mar; 130(3):159-69. doi:
10.1016/j.jphs.2016.02.003. [PMID: 26970780] - Shoji Takakura, Tohru Toyoshi, Yuka Hayashizaki, Toshiyuki Takasu. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Life sciences.
2016 Feb; 147(?):125-31. doi:
10.1016/j.lfs.2016.01.042. [PMID: 26829386] - Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Archives of pharmacal research.
2016 Feb; 39(2):259-270. doi:
10.1007/s12272-015-0621-8. [PMID: 26450351] - Hideo Okonogi, Mikio Harada, Hironobu Sato, Kazuhiko Tokoro, Issei Nakayama, Nobuo Tsuboi, Yoichi Miyazaki, Tetsuya Kawamura, Makoto Ogura, Takashi Yokoo. Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury.
Internal medicine (Tokyo, Japan).
2016; 55(14):1887-91. doi:
10.2169/internalmedicine.55.5482. [PMID: 27432098] - Akinori Hayashi, Koji Takano, Sayuki Kawai, Masayoshi Shichiri. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
Endocrine journal.
2016; 63(2):187-91. doi:
10.1507/endocrj.ej15-0523. [PMID: 26549210] - Yasushi Honda, Kento Imajo, Takayuki Kato, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Hironori Mawatari, Koji Fujita, Masato Yoneda, Satoru Saito, Atsushi Nakajima. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
PloS one.
2016; 11(1):e0146337. doi:
10.1371/journal.pone.0146337. [PMID: 26731267] - Kuralay Atageldiyeva, Yukihiro Fujita, Tsuyoshi Yanagimachi, Katsutoshi Mizumoto, Yasutaka Takeda, Jun Honjo, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Masakazu Haneda. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
PloS one.
2016; 11(6):e0157672. doi:
10.1371/journal.pone.0157672. [PMID: 27327650] - Shinji Kobuchi, Yukako Ito, Kyoka Yano, Toshiyuki Sakaeda. A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Sep; 1000(?):22-8. doi:
10.1016/j.jchromb.2015.07.013. [PMID: 26209767]